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Introduction
Patients with end-stage renal disease (ESRD) have high rates of mortality and morbidity. Adequate dialysis is essential to maintain a high quality of life and survival in these patients. Vascular access is also known as a 'lifeline' for patients receiving hemodialysis (HD). The patency and rate of blood flow of vascular access are directly associated with dialysis adequacy. Complications associated with vascular access result in frequent hospitalizations and often require intervention. These complications have significant impacts on the morbidity and mortality of dialysis patients, while also leading to high medical costs. [1] [2] [3] [4] [5] As a result, having a well-functioning point of vascular access is very important.
Vascular access for HD patients can be achieved via native arteriovenous fistulas (AVF), synthetic arteriovenous grafts (AVG) or central vein catheters. The most common cause of AVF or AVG dysfunction is thrombosis, 6 and several medications have been used to prevent vascular access thrombosis, including anticoagulants and antiplatelet agents. In 2014, a meta-analysis showed that AVFs had a high rate of primary failure, with low-to-moderate primary and secondary patency rates. 7 Vascular access thrombosis is one of the most common complications of dialysis shunts that is initiated by neointimal vascular smooth muscle cell proliferation. [8] [9] [10] Furthermore, platelet activation plays an important role in this pathogenesis. Over the past few decades, different medications have been studied for the prevention of vascular access thrombosis, including antiplatelet agents and warfarin. The use of antiplatelet agents has been aimed at preventing neointimal hyperplasia. Some studies have discussed the efficacy and treatment complications associated with these agents for thrombosis prevention. [11] [12] [13] Vascular access patency was the most demonstrated benefit of antiplatelet agents, but their impact on the risk of bleeding was inconclusive. To our best knowledge, there have been no large-scale studies that performed head-to-head comparisons of these agents regarding their efficacy for thrombosis prevention or their impact on the risk of major bleeding.
This study used a nationwide cohort of patients with ESRD using AVF or AVG for vascular access to estimate the efficacy of thrombosis prevention and the risk of major bleeding with different antiplatelet agents and oral anticoagulants.
Study design

Ethical approval and consent to participate
This study was approved by the institutional review board of the Chang Gung Memorial Hospital, Taoyuan, Taiwan (IRB no: 201800379B1), and informed consent was waived as no identifiable information was used in this study.
Data source
This retrospective cohort study investigated all patients with ESRD who were registered in the Taiwan National Health Insurance (NHI) program from 1 January 1997 to 31 December 2012. The NHI program in Taiwan was founded in 1995 as a single-payer insurance system. All citizens and foreigners living in Taiwan for more than 6 months must join the NHI program by law. Approximately 23 million beneficiaries were registered in the NHI in 2013, and the coverage rate is more than 99.5%. The NHI maintains an anonymous database that records comprehensive characteristics of all beneficiaries, including medical diagnosis, examinations, surgical procedures, detailed prescriptions and incurred fees.
Identifying ESRD
The Ministry of Health and Welfare in Taiwan has a list of catastrophic illnesses. Patients with ESRD who required dialysis or who had cancer, a chronic mental illness or congenital disorders are included in this list and might have incurred substantial medical expenditures, as well as large copayments. Any insured individual with a catastrophic illness certificate is exempt from such copayments. The issuance of catastrophic illness certificates requires a prior review by at least two specialists, as well as a careful examination of medical records, laboratory results and imaging studies.
In this study, all dialysis patients were obtained from the Registry of Catastrophic Illness Database, a subset of the NHI Research Database. The diagnostic codes are based on the International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM). Patients enrolled in this study were diagnosed with ESRD based on ICD-9-CM code 585.
Study population
All patients who were diagnosed with ESRD from 1 January 1997 to 31 December 2012 were included in this study. We excluded patients who did not receive HD or who did not have AVF or AVG performed (procedure codes: 69032C, 69038C, 69032CC). Figure 1 shows the flow diagram of our study.
Event outcomes
Identifying AVF or AVG dysfunction thrombosis in the NHI research database. Patients with ESRD who received AVF or AVG percutaneous angioplasty (PTA) or surgical thrombectomy were defined as having an AVF or AVG failure/thrombosis. Using specific procedure codes, we could identify these patients. The procedure codes for PTA in the NHI research database were 33074B and for thrombectomy were 58004C, 58005C and 58006C.
Major bleeding. Major bleeding was defined as a hospitalization or an emergency department visit with a primary diagnosis of intracranial hemorrhage (ICH) or gastrointestinal (GI) bleeding. People with a traumatic ICH were excluded from the analysis.
Person-quarters
Each calendar year was partitioned into four quarters for each patient and each year after the first prescription of antiplatelet agents or oral anticoagulants, with an analytic unit of one person-quarter. 14 We used this method because medications for chronic illnesses were refilled with a maximum duration of 3 months per the Taiwan NHI reimbursement policy. Medications and covariates were assessed for each person-quarter, and person-quarters exposed to antiplatelet agents or oral anticoagulants were identified. AVF or AVG dysfunction, as well as the major bleeding risks of person-quarters with exposure to antiplatelet agents or oral anticoagulants, were compared with person-quarters with no exposures to these drugs.
Antiplatelet agents and oral anticoagulants
Antiplatelet agents including aspirin, clopidogrel, dipyridamole, Aggrenox (a combination of aspirin and dipyridamole) and warfarin were studied. Patients who took two or more of these drugs were excluded from our study.
Covariates
Sex, age, socioeconomic status and comorbidities for the patients were identified as covariates. These covariates were assessed for each person-quarter pertinent to the first date of the person-quarter. The components of the Charlson comorbidity index (myocardial infarction, congestive heart disease, peripheral vascular disease, cerebrovascular disease, dementia, chronic pulmonary disease, rheumatologic disease, peptic ulcer disease, mild liver disease, moderate or severe liver disease, diabetes, diabetes with complications, hemiplegia and paraplegia, any malignancy including leukemia and lymphoma, metastatic tumors, and human immunodeficiency virus infection) were identified. Details of the case definitions are listed in Table S1 .
Propensity score
The selection of one medication over another is confounded by the indication and may result in a non-random treatment allocation. We used the inverse probability of treatment weighting to account for this bias using a propensity score. 15 The propensity score was the probability that a patient was prescribed the concurrent medication during a person-quarter. For each person, a specific propensity score was calculated using a logistic regression that considered the aforementioned covariates that were pertinent to the first date of the person-quarter.
Statistical analysis
The demographic characteristics were displayed between patients with exposure to any of the medications of interest among patients' person-quarters and patients without exposure. The generalized estimating equation (GEE) 16 was used to calculate the adjusted odds ratio (OR) of events of interest between person-quarters with exposure of drug and person-quarters without exposure. The OR and a 95% confident interval with consideration of the propensity score weighting of vascular access failure or major bleeding for each medication were calculated. We used the correlation structure of the GEE to account for the correlation within subject because the person-quarters belonging to same subject may be dependent. A significance threshold of 0.05 was used in this study. Data from patients without a valid insurance status were considered missing data and were excluded from this study (estimated at less than 0.1% in ESRD patients). The analysis was performed using SAS (SAS Institute) version 9.4.
Results
From 1997 to 2012, a total of 173 530 patients with ESRD were identified. Of these, patients who did not undergo HD (n = 24 922), or who did not have any AVF or AVG access created (n = 52 616), or patients who took two or more antiplatelet agents or combined antiplatelet agent and warfarin use at the same time (n = 21), were excluded. A total of 95 971 patients were enrolled in our study ( Fig. 1) . We calculated the incidence rates for the person-quarters. There were 1 503 250 person-quarters for patients with ESRD in this study. Eligible study subjects were further categorized into five groups that were based on which medicine was administered.
Detailed demographic data for these patients are shown in Table 1 .
Preventing AVF or AVG failure/thrombosis
The adjusted OR and 95% confidence interval (CI) of AVF or AVG failure/thrombosis were 0.21 (0.11-0.39) for aspirin, 0.76 (0.74-0.79) for clopidogrel, 0.67 (0.59-0.77) for dipyridamole, 0.67 (0.53-0.86) for Aggrenox and 0.96 (0.90-1.03) for warfarin. All data are shown in Table 2 . We then investigated whether these antiplatelet agents or oral anticoagulants had protective effects on vascular patency in patients. The patients were further divided into subgroups corresponding to their sex and age, with similar results. The protective effect of warfarin only appeared in older (age > 50 years) patients, with an OR (95% CI) of 0.92 (0.86-0.99). In younger (aged ≤ 50 years) patients, the OR (95% CI) was 1.34 (1.12-1.61) for warfarin in this group.
Major bleeding events
Intracerebral bleeding. The highest OR (95% CI) for intracerebral hemorrhage (ICH) was 5.33 (1.25-22.72) in younger (aged < 50 years) patients using Aggrenox (Table 3) . No significant sex difference was noted for bleeding risk.
Warfarin also carried a higher risk of ICH. The OR (95% CI) for ICH with warfarin use was 1.36 (1.01-1.84). Older patients (aged > 50 years) had a higher ICH risk, with an OR (95% CI) of 1.40 (1.02-1.91). No significant sex difference was noted in this group.
Other antiplatelet agents did not significantly increase the ICH risk.
GI tract bleeding. No GI tract bleeding event was noted in the aspirin treatment group. The OR (95% CI) for GI tract bleeding was 1.34 (1.10-1.64) for clopidogrel, 0.42 (0.11-1.70) for dipyridamole, 0.75 (0.10-5.36) for Aggrenox and 1.30 (0.79-2.12) for warfarin (Table 4) .
Clopidogrel was the only agent that increased GI tract bleeding, especially in older patients, with an OR (95% CI) of 1.30 (1.06-1.60), and in female patients, with an OR (95% CI) of 1.41 (1.08-1.84). A forest plot of the adjusted ORs for the different medications is shown in Fig. 2 .
Discussion
Venipuncture during dialysis sessions, shear stress from turbulent flow and hemodynamic instability during dialysis may cause vascular endothelial cell injury, which leads to neo-intimal hyperplasia and smooth muscle cell proliferation. 17, 18 This issue causes the vessels to become stenotic and leads to subsequent thrombosis. Antiplatelet therapy may inhibit neo-intimal hyperplasia 19 ; thus, it is reasonable to use these agents to prevent vascular access failure.
Our study demonstrated that antiplatelet therapy might reduce vascular access failure rates. Among these therapeutic agents, aspirin was the most effective agent with an OR (95% CI) of 0.21 (0.11-0.39). Aspirin inhibits cyclooxygenase and suppresses platelet activation. 20 Aspirin also inhibits P-selectin, which impairs the recruitment of neutrophils to the vascular endothelium. 21 In addition to its anti-inflammatory effects and its impact on platelet inhibition, aspirin reduces thrombin levels and factor XIII activation. 22 These characteristics might explain why it is effective for preventing vascular access failure.
Dipyridamole, a phosphodiesterase inhibitor and adenosine reuptake inhibitor, might moderately reduce the vascular access failure rate, with an OR (95% CI) of 0.67 (0.59-0.77). Dipyridamole has pleiotropic effects. Dipyridamole inhibits platelet aggregation, inhibits smooth muscle cells proliferation, and inhibits the formation of MCP-1 and MMP-9, which are known pro-inflammatory cytokines. Inflammation is a well-known potent prothrombotic stimulus and inflammatory mediators may increase platelet reactivity. 23 Clopidogrel is an adenosine diphosphate receptor inhibitor that inhibits the aggregation of platelets. Clopidogrel has widely been used to prevent stroke and ischemic heart disease. In our study, we found that clopidogrel reduced the rate of AVF failure with an OR (95% CI) of 0.76 (0.74-0.79). Another study with similar results found that clopidogrel reduced the frequency of early thrombosis of new AVFs.
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A meta-analysis showed that antiplatelet treatment protected fistulas from thrombosis or loss of patency. 11 Another study showed that combined treatment with dipyridamole and aspirin had a modest effect on reducing the risk of stenosis for newly created grafts, with no increase in the bleeding rate during active treatment. 13 Some randomized control trials demonstrated a trend or significant but modest effects of these agents in AV shunt patency. 13, [25] [26] [27] However, some studies failed to demonstrate any improvement in vascular patency. [28] [29] [30] [31] There were some advantages to our study design. First, our study was a nationwide, population-based study with a large number of enrolled dialysis patients that might be close to the 'real world' data. Second, this study examined common antiplatelet agents that are used in daily clinical practice, which might provide clinicians with more information regarding drug choices.
Warfarin, a vitamin K antagonist, has a proven beneficial impact on AVG patency, 32 and this effect was only demonstrated in older patients in our study. Because ours was a registry database study, we did not have the detailed international normalized ratio (INR) of each patient. One retrospective study enrolled 7278 patients in Taiwan with varying indications of warfarin usage and a AVF, arteriovenous fistula; AVG, arteriovenous graft. *P < 0.05. †Using the inverse probability of treatment weights for the propensity score (sex, age, myocardial infarction, congestive heart disease, peripheral vascular disease, cerebrovascular disease, dementia, chronic pulmonary disease, rheumatological disease, peptic ulcer disease, mild liver disease, moderate or severe liver disease, diabetes, diabetes with complications, hemiplegia and paraplegia, any malignancy including leukemia and lymphoma, metastatic tumors, and hypertension). mean patient INR of 2.0. 33 Another study enrolled 563 Taiwanese patients after a mechanical valve replacement and the mean INR was 1.86 with no increase in thromboembolism. 34 Regarding warfarin doses, racial and ethnic differences have been studied. A lower dose of warfarin was required for Asian patients, and this difference in required dosage might be caused by a variation in CYP2C9 and VKORC1. [35] [36] [37] Moreover, another study revealed that Han Chinese individuals require a lower mean warfarin dose than Caucasians do. 38 Additionally, a lower optimal target range for INR was suggested in both Han Chinese and Japanese patients. [39] [40] [41] However, the protective effects of warfarin were not observed in younger patients, indicating that their dose requirements for the drug might be higher. 42 Another study found that young age was associated with warfarin non-adherence in heart failure patients. 43 Young age was also associated with improved longevity for vascular access. 44, 45 These findings might explain why warfarin showed no benefit for the younger patients in our study.
A previous randomized controlled trial examined the effect of a low-intensity warfarin treatment vs. placebo in 2002. 32 There was a significant increase in bleeding in the treatment group and the study was terminated early. Our study showed that warfarin had a modest risk of ICH (OR, 1.36; 95% CI, 1.01-1.84), especially in older patients, with an OR (95% CI) of 1.40 (1.02-1.91).
Aggrenox, a combination of aspirin and extendedrelease dipyridamole, was also effective in preventing AVF or AVG failure, with an OR (95% CI) of 0.67 (0.53-0.86). Similar to warfarin, we observed a diminished protective effect in younger patients. However, the OR for ICH in Aggrenox users was significantly increased in younger patients. According to a literature review and meta-analysis data, the risk of ICH was greater among patients receiving dual antiplatelet therapy than among those receiving clopidogrel monotherapy. 46 Young adults with ICH have a high mortality rate, and the most common risk factor was hypertension. 47 This drug should be prescribed with caution, especially for high-risk patients.
A modest increase in the risk of GI bleeding was observed in the clopidogrel group in our study, with an OR (95% CI) of 1.34 (1.10-1.64). A previous study found that patients prescribed clopidogrel had a greater rate of recurrent GI bleeding than those with a combined prescription of aspirin plus a proton pump inhibitor. 48 Aspirin reduces the formation of prostaglandins, which are protective of the gastric mucosa, and is thought to increase the rate of GI bleeding. However, our data showed that aspirin is safer than clopidogrel regarding the GI bleeding risk, regardless ICH, intracerebral hemorrhage. *P < 0.05. †Using the inverse probability of treatment weights of the propensity score (sex, age, myocardial infarction, congestive heart disease, peripheral vascular disease, cerebrovascular disease, dementia, chronic pulmonary disease, rheumatological disease, peptic ulcer disease, mild liver disease, moderate or severe liver disease, diabetes, diabetes with complications, hemiplegia and paraplegia, any malignancy including leukemia and lymphoma, metastatic tumors, and hypertension).
of proton pump inhibitor use. Another study showed that clopidogrel reduced the frequency of AVF thrombosis but did not discuss this side-effect.
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Limitations
There were several limitations in the present study. First, this was a database cohort study; thus, we did not have detailed information regarding the laboratory data or the exact effect of warfarin in our patients (i.e. INR level). We did not have detailed medical records for each patient; the indication for each medication and these records might result in non-random treatment allocation. Confounding by indication bias could exist in our study. To account for this bias, we used the inverse probability of treatment weighting by propensity score. Second, the identification of ESRD was based on the diagnosis recorded in the registry of patients with catastrophic illnesses. We did not have detailed information on the clinical findings or the definitive cause of ESRD. At least two nephrologists validated the issuance of the catastrophic illness certificates after a careful examination of the medical records, laboratory studies and imaging studies; therefore, our definition was stringent. Third, the dosage of antiplatelet drugs and warfarin was not considered in our model because it would have been too complicated for our model calculation. Fourth, the bleeding risk associated with warfarin treatment in an Asian population is known to differ from that of a Western population. The external generalizability of our results is limited, especially to patients from Western populations. Fifth, there might be very few patients who did not receive interventions after they experienced vascular access failure and they would not be recorded as having a 'failure event' in our study. This might underestimate the vascular access failure rate.
Conclusions
Antiplatelet agents, including aspirin, clopidogrel and dipyridamole, might reduce the rate of AVF or AVG failure. Aspirin was an effective agent in preventing arteriovenous shunt failure without increasing the rate of GI bleeding. However, the GI bleeding rate was increased with concomitant use of clopidogrel. The combination of aspirin and dipyridamole may increase the rate of ICH in younger patients. Taking warfarin did not reduce the rate of AVF or AVG failure but increased the rate of ICH in our patients. These medications should be prescribed with caution for patients at a high risk of bleeding. GI, gastrointestinal; OR, odds ratio; N/A, not applicable. *P < 0.05. †Using the inverse probability of treatment weights of the propensity score (sex, age, myocardial infarction, congestive heart disease, peripheral vascular disease, cerebrovascular disease, dementia, chronic pulmonary disease, rheumatological disease, peptic ulcer disease, mild liver disease, moderate or severe liver disease, diabetes, diabetes with complications, hemiplegia and paraplegia, any malignancy including leukemia and lymphoma, metastatic tumors, and hypertension). 
